La Jolla Pharmaceutical Company (LJPC)

NASDAQ: LJPC · IEX Real-Time Price · USD
3.16
+0.04 (1.28%)
Jul 5, 2022 4:30 PM EDT - Market closed

Company Description

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases.

The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.

It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia.

The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA.

La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company Logo
Country United States
Founded 1989
IPO Date Jun 3, 1994
Industry Biotechnology
Sector Health Care
Employees 61

Contact Details

Address:
4550 Towne Centre Ct
San Diego, California 92121-1900
United States
Phone 617 715 3600
Website lajollapharmaceutical.com

Stock Details

Ticker Symbol LJPC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0000920465
CUSIP Number 503459505
ISIN Number US5034596040
Employer ID 33-0361285
SIC Code 2836

Key Executives

Name Position
Larry G. Edwards President, Chief Executive Officer and Director
Michael S. Hearne Chief Financial Officer and Secretary
Paula Rusu Vice President of Operations
Sandra Vedrick Senior Director of Investor Relations and Human Resources
Luke Seikkula Senior Vice President of Pharmaceutical Operations
Dr. Lakhmir S. Chawla M.D. Consultant
Stewart M. Kroll Chief Development Officer
Mark D. Williams Senior Vice President of Medical Affairs
Tony N. Hodges FACP, M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 2, 2022 4 Statement of changes in beneficial ownership of securities
May 17, 2022 4 Statement of changes in beneficial ownership of securities
May 16, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 3, 2022 4 Statement of changes in beneficial ownership of securities
May 2, 2022 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
Apr 18, 2022 4 Statement of changes in beneficial ownership of securities
Apr 18, 2022 4 Statement of changes in beneficial ownership of securities
Apr 4, 2022 4 Statement of changes in beneficial ownership of securities
Apr 4, 2022 4 Statement of changes in beneficial ownership of securities